Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT.

abstract：:Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhan...

journal_title：Bone marrow transplantation

authors： Kobold S,Isernhagen J,Hübel K,Kilic N,Bogner C,Frickhofen N,Bokemeyer C,Fiedler W

更新日期：2011-08-01 00:00:00

abstract：:NK cells can exert potent anti-leukemia activity after either autologous or allogeneic BMT. However, in autologous blood or marrow transplant patients, NK cell number and/or function could be reduced, and also may vary according to the sampling site. In order to evaluate the hypothesis that blood or marrow grafts from...

journal_title：Bone marrow transplantation

authors： Arbour S,Toupin S,Bélanger R,Gyger M,Hallé JP,Perreault C,Roy DC

更新日期：1996-03-01 00:00:00

abstract：:We showed previously that transplantation of 10(7) unmanipulated C57BL/6 marrow cells to irradiated LP mice yields healthy (B6-LP) chimeras showing no signs of rejection or graft-versus-host disease (GVHD). The aim of this work was to gain more insight into the mechanism(s) responsible for tolerance to host minor hist...

journal_title：Bone marrow transplantation

authors： Perreault C,Allard A,Brochu S,Poupart C,Fontaine P,Bélanger R,Gyger M

更新日期：1990-08-01 00:00:00

abstract：:In this retrospective study, we evaluated the predictability of PBSC dose for hematopoietic engraftment comparing that calculated by ideal body weight (IBW) vs another calculated by actual body weight (ABW) for each patient. Sixty-three consecutive patients treated similarly using one transplant protocol were analyzed...

journal_title：Bone marrow transplantation

authors： Waples JM,Moreb JS,Sugrue M,Belanger G,Kubilis P,Lynch JW,Gian V,Weeks F,Wingard J

更新日期：1999-05-01 00:00:00

abstract：:The aim of this phase II study was to determine the feasibility of using two (tandem) courses of high-dose alkylating agents with bone marrow or peripheral blood progenitor cell support in women with stage IV breast cancer. Women with stage IV breast cancer who had achieved a CR or PR during conventional chemotherapy ...

journal_title：Bone marrow transplantation

authors： Bitran JD,Samuels B,Klein L,Hanauer S,Johnson L,Martinec J,Harris E,Kempler J,White W

更新日期：1996-02-01 00:00:00

abstract：:Liver dysfunction is a common problem in BMT recipients and it is important to determine the etiology in order to institute appropriate therapy. The purpose of this study was to evaluate the possible causes of liver dysfunction during the first post-transplant year in BMT recipients and to identify a possible relation...

journal_title：Bone marrow transplantation

authors： Kim BK,Chung KW,Sun HS,Suh JG,Min WS,Kang CS,Sim SI,Shin WS,Kim CC

更新日期：2000-07-01 00:00:00

abstract：:During the past few years major progress has been made in the diagnosis and therapy of CMV infection after allogeneic BMT. The aim of this survey was to investigate the use of diagnostic techniques, use of prophylaxis and the therapeutic strategies among members of the EBMT. Seventy centers from 20 countries responded...

journal_title：Bone marrow transplantation

authors： Ljungman P,De Bock R,Cordonnier C,Einsele H,Engelhard D,Grundy J,Locasciulli A,Reusser P,Ribaud P

更新日期：1993-10-01 00:00:00

abstract：:Authors report a case of P. carinii pneumonia in a child with 5% CD4 lymphocytes (absolute number 5/microliters) after autologous bone marrow transplantation followed by pulmonary irradiation. Serial evaluation of CD4 lymphocyte count or percentage or, at least, detection of significant and persistent lymphopenia coul...

journal_title：Bone marrow transplantation

authors： Castagnola E,Dini G,Lanino E,Tasso L,Dallorso S,Garaventa A,Rossi GA,Giacchino R

更新日期：1995-06-01 00:00:00

abstract：:Identifying risk factors that lead to graft failure may reduce morbidity and mortality after bone marrow transplantation (BMT) for hematologic malignancies. We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an...

journal_title：Bone marrow transplantation

authors： Schultz KR,Ratanatharathorn V,Abella E,Eisenbrey AB,Karanes C,Lum LG,de Planque MM,Uberti JP,Ravindranath Y,Sensenbrenner LL

更新日期：1994-06-01 00:00:00

abstract：:Umbilical cord blood (UCB) is a readily available source of hematopoietic stem cells for transplantation. UCB hematopoietic SCT for average- and large-sized patients is often limited by the number of cells available in a single unit. To address this limitation, we performed experiments to determine if adjunctive thera...

journal_title：Bone marrow transplantation

authors： Budak-Alpdogan T,Jeganathan G,Lee KC,Mrowiec ZR,Medina DJ,Todd D,Moore D,Bertino JR,Strair R

更新日期：2012-12-01 00:00:00

abstract：:Between July 1990 and March 2002, 35 consecutive children with ALL in third complete remission (CR3) underwent stem cell transplantation (SCT) from unrelated donors (UD). All patients received CAMPATH-1M 5-20 mg daily for 5 days. Grafts were T-cell depleted in 30 patients, 29 by CAMPATH antibodies and one by CD34 sele...

journal_title：Bone marrow transplantation

authors： Afify Z,Hunt L,Green A,Guttridge M,Cornish J,Oakhill A

更新日期：2005-06-01 00:00:00

abstract：:Up to now there are no data on long-term effects of allogeneic peripheral blood cell transplantation (AlloPBPCT). In particular, long term effects on healthy donors by the mobilization procedure which includes the exposition to G-CSF over several days are unknown. Recently the possibility of an increase in risk for ac...

journal_title：Bone marrow transplantation

authors： Hasenclever D,Sextro M

更新日期：1996-03-01 00:00:00

abstract：:CTLA-4 is a negative regulator of activated T cells and the association of CTLA-4 polymorphisms with autoimmune diseases and transplant outcome has been reported. We evaluated the effect of donor CTLA-4 polymorphisms on outcome after allogeneic hematopoietic SCT (HSCT). We analyzed 147 Japanese HLA-matched sibling rec...

journal_title：Bone marrow transplantation

authors： Murase M,Nishida T,Onizuka M,Inamoto Y,Sugimoto K,Imahashi N,Murata M,Miyamura K,Kodera Y,Inoko H,Naoe T

更新日期：2011-11-01 00:00:00

abstract：:Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) is an alternative for patients who need a transplant without having conventional donors. One hundred and five consecutive patients with hematologic malignancies who underwent G-CSF-primed peripheral blood haplo-HSCT without in vitro T-cell depletion i...

journal_title：Bone marrow transplantation

authors： Lin X,Lu ZG,Song CY,Huang YX,Guo KY,Deng L,Tu SF,He YZ,Xu JH,Long H,Wu BY

更新日期：2015-08-01 00:00:00

abstract：:Relapsed disease remains a major obstacle following autologous haematopoietic SCT (HSCT) for non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Studies regarding the importance of detectable tumour cells in PBSC collections have been inconclusive. Patients undergoing autologous HSCT for NHL and MM between 2001 an...

journal_title：Bone marrow transplantation

authors： Ho J,Yang L,Banihashemi B,Martin L,Halpenny M,Atkins H,Sabloff M,McDiarmid SA,Huebsch LB,Bence-Bruckler I,Giulivi A,Allan DS

更新日期：2009-02-01 00:00:00

abstract：:Among 42 consecutive recipients of unrelated marrow were 39 HLA-A, -B, -DR identical, matched unrelated donors (MUD) and three with one HLA antigen mismatch. The majority were genomically typed for DRB, DQA, DQB and DPB. The recipients of MUD marrow were compared with 39 recipients of marrow from HLA-identical sibling...

journal_title：Bone marrow transplantation

authors： Ringdén O,Remberger M,Persson U,Ljungman P,Aldener A,Andström E,Aschan J,Bolme P,Dahllöf G,Dalianis T

更新日期：1995-04-01 00:00:00

abstract：:The aim of the present trial was to investigate the feasibility of high-dose therapy followed by autologous peripheral blood stem cell transplantation (PBSCT) as a component of front-line treatment in patients with disseminated intermediate- and high-grade non-Hodgkin's lymphoma (NHL) aged 61-65 years. From October 19...

journal_title：Bone marrow transplantation

authors： Moreau P,Milpied N,Voillat L,Colombat P,Mahé B,Rapp MJ,Moreau A,Dupas B,Bulabois CE,Juge-Morineau N,Harousseau JL

更新日期：1998-06-01 00:00:00

abstract：:While prospects for long-term survival following bone marrow transplantation (BMT) have increased, little is known about the quality of that survival. The present study was intended to document the physical and psychosocial functioning of survivors of allogeneic BMT as well as identify factors associated with variabil...

journal_title：Bone marrow transplantation

authors： Andrykowski MA,Henslee PJ,Farrall MG

更新日期：1989-01-01 00:00:00

abstract：:Autologous hematopoietic stem cell transplantation (HSCT) is currently being evaluated as a therapy for patients with progressive multiple sclerosis (MS) at risk of debilitating neurological impairment. While preliminary results from a few studies have been reported, little is known about toxicities or outcome of HSCT...

journal_title：Bone marrow transplantation

authors： Oyama Y,Cohen B,Traynor A,Brush M,Rodriguez J,Burt RK

更新日期：2002-01-01 00:00:00

abstract：:Although most children with ALL can be cured by chemotherapy approaches, allogeneic hematopoietic cell transplant (HCT) therapy offers a better chance of cure to selected high-risk patients in first remission and most children who relapse. Although transplant-related mortality has decreased significantly in the past d...

journal_title：Bone marrow transplantation

authors： Pulsipher MA,Wayne AS,Schultz KR

更新日期：2014-10-01 00:00:00

abstract：:In all, 30 patients with CLL proceeded to myeloablative allogeneic BMT using related (n=20, 67%) or unrelated (n=10) donors, at the Princess Margaret Hospital (Toronto) (n=20) or the Leukemia/BMT Program of BC (Vancouver) (n=10), from 1989 to 2001. Median (range) interval from diagnosis to BMT was 4.8 (0.3-13) years, ...

journal_title：Bone marrow transplantation

authors： Toze CL,Galal A,Barnett MJ,Shepherd JD,Conneally EA,Hogge DE,Nantel SH,Nevill TJ,Sutherland HJ,Connors JM,Voss NJ,Kiss TL,Messner HA,Lavoie JC,Forrest DL,Song KW,Smith CA,Lipton J

更新日期：2005-11-01 00:00:00

abstract：:The safety of injecting healthy donors with granulocyte colony-stimulating factor (G-CSF) has not been established. To evaluate PBSC mobilization and harvesting efficacy in the pediatric population, we compared it with those in adult donors. In this study, we conclude that PBSC mobilization and harvesting protocol in ...

journal_title：Bone marrow transplantation

authors： Kawano Y,Takaue Y,Watanabe T,Watanabe A,Iwai A,Kuroda Y

更新日期：1998-06-01 00:00:00

abstract：:The physical and psychosocial consequences for patients undergoing blood SCT for the treatment of cancer and their families have been extensively documented. There has, however, been far less investigation into the psychosocial consequences for sibling donors who are both family members and undergoing an invasive medi...

journal_title：Bone marrow transplantation

authors： Pillay B,Lee SJ,Katona L,De Bono S,Warren N,Fletcher J,Burney S

更新日期：2012-10-01 00:00:00

abstract：:The aim of this study was to compare anxiety, pain and discomfort of cancer patients submitted to either peripheral blood progenitor cell collection (PBPCC) or bone marrow harvest (BMH). Patients, randomized (7/1993-2/1994), in view of autograft, to receive the first procedure or the second one, completed self-adminis...

journal_title：Bone marrow transplantation

authors： Auquier P,Macquart-Moulin G,Moatti JP,Blache JL,Novakovitch G,Blaise D,Faucher C,Viens P,Maraninchi D

更新日期：1995-10-01 00:00:00

abstract：:In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly nonmyeloablative (NM; 90 mg/m(2) fludarabine, 2 Gy TBI) hematopoietic SCT (HSCT) from unrelated donors. Median patient age was 51 years (range, 25-67 years). After a median...

journal_title：Bone marrow transplantation

authors： Zohren F,Schroeder T,Czibere A,Fenk R,Bruns I,Kondakci M,Saure C,Haas R,Kobbe G

更新日期：2011-05-01 00:00:00

abstract：:Complex factors determine how physicians select between alternative therapies. We conducted a survey of 352 leukemia experts to determine consensus regarding optimal treatment for leukemia and to identify factors correlated with therapy decisions. The study evaluated both general treatment policies and recommendations...

journal_title：Bone marrow transplantation

authors： Atkinson KA,Horowitz MM,Sobocinski KA,Rimm AA,Bortin MM,Gale RP

更新日期：1992-01-01 00:00:00

abstract：:Expression of the chemokine receptor CXCR4 on human haemopoietic stem cells (HSC) may play a crucial role in localising these cells to the bone marrow. To evaluate whether CXCR4 expression is clinically relevant we have enumerated CXCR4-positive HSC used for allogeneic transplantation and sought any relationship with ...

journal_title：Bone marrow transplantation

authors： Spencer A,Jackson J,Baulch-Brown C

更新日期：2001-12-01 00:00:00

abstract：:Reverse transcriptase polymerase chain reaction (RT-PCR) was applied to evaluate the frequency of tumour cells in PBPC products from 15 high risk Ewing tumour (ET) patients who were treated according to EICESS 92 with high-dose chemotherapy (HDC) and stem cell rescue. Initial tumour cell contamination of the bone marr...

journal_title：Bone marrow transplantation

authors： Fischmeister G,Zoubek A,Jugovic D,Witt V,Ladenstein R,Fritsch G,Höcker P,Gadner H,Kovar H

更新日期：1999-08-01 00:00:00

abstract：:We investigated the proliferation and therapeutic utility of anti-CD3 activated splenocytes infused into mice following BMT. Using congenic mouse strains we demonstrated that splenocytes activated briefly ex vivo with anti-CD3 plus IL-2 (T-activated killer cells or T-AK) and infused intravenously following BMT had a g...

journal_title：Bone marrow transplantation

authors： Katsanis E,Xu Z,Anderson PM,Dancisak BB,Bausero MA,Weisdorf DJ,Blazar BR,Ochoa AC

更新日期：1994-10-01 00:00:00

abstract：:Although intensive therapy with autologous bone marrow transplantation (ABMT) has improved the outcome of advanced neuroblastoma, nearly half the patients with this disease still relapse after a single ABMT. In our previous study, 10 of 22 patients relapsed within 16 months post-transplantation. Predictive risk-factor...

journal_title：Bone marrow transplantation

authors： Kawa-Ha K,Yumura-Yagi K,Inoue M,Park DY,Okamura T,Yasui M,Oota H,Sakata N,Yoneda M,Imura K

更新日期：1996-06-01 00:00:00